New hope for kids with tough cancers: immunotherapy drug tested
NCT ID NCT02332668
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrink tumors. The study is currently recruiting participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Call for Information (Investigational Site 0019)
RECRUITINGAurora, Colorado, 80045, United States
-
Call for Information (Investigational Site 0024)
RECRUITINGChicago, Illinois, 60637, United States
-
Call for Information (Investigational Site 0026)
RECRUITINGBoston, Massachusetts, 02445, United States
-
Call for Information (Investigational Site 0031)
RECRUITINGNew York, New York, 10032, United States
-
Call for Information (Investigational Site 0054)
RECRUITINGDallas, Texas, 75235, United States
-
Call for Information (Investigational Site 0070)
RECRUITINGFargo, North Dakota, 58102, United States
-
Call for Information (Investigational Site 0071)
RECRUITINGSioux Falls, South Dakota, 57117, United States
-
MSD Brasil
RECRUITINGSão Paulo, Brazil
-
MSD France
RECRUITINGParis, France
-
MSD Italia S.r.l.
RECRUITINGRome, Italy
-
MSD Korea LTD
RECRUITINGSeoul, 4130, South Korea
-
MSD Sharp & Dohme GmbH
RECRUITINGMünchen, Germany
-
MSD Sweden
RECRUITINGStockholm, Sweden
-
Merck Sharp & Dohme Co. Ltd.
RECRUITINGHod HaSharon, Israel
-
Merck Sharp & Dohme Lda.
RECRUITINGPaço de Arcos, Portugal
-
Merck Sharp & Dohme Ltd.
RECRUITINGLondon, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can new drug cocktails reawaken the immune system against melanoma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?